Movers and SHAKERS
Avivagen Inc. (VIVXF)
The China Road Is Now Open
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.China Approval. Avivagen's oxidized carotenoid-based feed additive, OxC-beta, has received approval for use in China. This is a significant accomplishment for Avivagen and should have a positive impact on operating results going forward. China marks the second key market, along with Vietnam, in which OxC-beta has received approval this year. With China and Vietnam approvals and the land-mark eight-year deal with AB Vista for exclusive distribution of OxC-beta for use with poultry, swine, ruminants (dairy and beef), and aquaculture in the U.S., Brazil, and Thailand, we believe Avivagen is on the cusp of significant revenue growth.
Number 1. China is the world's largest feed market. According to Alltech Agri-Food Outlook, the country will produce over 261 million metric tons of feed in 2022. In addition, the country also experienced the largest increase in feed production by tonnage during 2021, as the country’s feed industry continues to consolidate and modernize. China has been a leader in efforts to reduce antibiotic use with livestock nationwide, in an effort to reduce antimicrobial-resistance in the region, which plays directly into OxC-beta's strengths....
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.